Psychotogenic drugs and delirium pathogenesis: The central role of the thalamus

Medical Hypotheses

Volumn 64, Issue 3, 2005, Pages 471-475

  Gaudreau, Jean David ^a,b   Gagnon, Pierre ^a,b,c  

^a UNIVERSITY OF QUEBEC   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c Maison Michel Sarrazin   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; ACETYLCHOLINE; ALKALOID; AMPHETAMINE; ATROPINE; BENZODIAZEPINE DERIVATIVE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; DOPAMINE; FENTANYL; METHADONE; MUSCARINIC RECEPTOR BLOCKING AGENT; MUSCIMOL; N ETHYL 3,4 METHYLENEDIOXYAMPHETAMINE; NEUROLEPTIC AGENT; OPIATE; PHENCYCLIDINE; PSYCHEDELIC AGENT; PSYCHOTROPIC AGENT; SCOPOLAMINE; TERTIARY AMINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ARTICLE; BRAIN DYSFUNCTION; BRAIN NERVE CELL; CONFUSION; CORPUS STRIATUM; DELIRIUM; DELUSION; DISEASE EXACERBATION; GABAERGIC SYSTEM; HALLUCINATION; HUMAN; NERVE PROJECTION; NEUROANATOMY; NEUROTRANSMISSION; PATHOGENESIS; PRIORITY JOURNAL; PSYCHOMOTOR ACTIVITY; PSYCHOSIS; SCHIZOPHRENIA; THALAMUS;

CEREBRAL CORTEX; CORPUS STRIATUM; DELIRIUM; DOPAMINE; GAMMA-AMINOBUTYRIC ACID; HUMANS; MODELS, NEUROLOGICAL; PSYCHOTROPIC DRUGS; SUBSTANTIA NIGRA; TEGMENTUM MESENCEPHALI; THALAMUS;

EID: 11144340901     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2004.08.007     Document Type: Article

References (29)

1. P.T. Trzepacz Is there a final common neural pathway in delirium? Focus on acetylcholine and dopamine Semin. Clin. Neuropsychiatry 5 2000 132 148
2. J.M. Flacker, and L.A. Lipsitz Neural mechanisms of delirium: current hypotheses and evolving concepts J. Gerontol. A: Biol. Sci. Med. Sci. 54 1999 B239 B246
3. A. Carlsson, N. Waters, and M.L. Carlsson Neurotransmitter interactions in schizophrenia-therapeutic implications Biol. Psychiatry 46 1999 1388 1395
4. A.B. Scheibel The thalamus and neuropsychiatric illness J. Neuropsychiatry Clin. Neurosci. 9 1997 342 353
5. J.H. Meador-Woodruff, S.M. Clinton, M. Beneyto, and R.E. McCullumsmith Molecular abnormalities of the glutamate synapse in the thalamus in schizophrenia Ann. N. Y. Acad. Sci. 1003 2003 75 93
6. N.C. Andreasen, S. Paradiso, and D.S. O'Leary "Cognitive dysmetria" as an integrative theory of schizophrenia: a dysfunction in cortical-subcortical-cerebellar circuitry? Schizophr. Bull. 24 1998 203 218
7. N.C. Andreasen The role of the thalamus in schizophrenia Can. J. Psychiatry 42 1997 27 33
8. E.G. Jones Cortical development and thalamic pathology in schizophrenia Schizophr. Bull. 23 1997 483 501
9. A. Carlsson The current status of the dopamine hypothesis of schizophrenia Neuropsychopharmacology 1 1988 179 186
10. E.K. Perry, and R.H. Perry Acetylcholine and hallucinations: disease-related compared to drug-induced alterations in human consciousness Brain Cogn. 28 1995 240 258
11. P.A. de Smet A multidisciplinary overview of intoxicating snuff rituals in the western hemisphere J. Ethnopharmacol. 13 1985 3 49
12. S.J. Eisendrath, B. Goldman, J. Douglas, L. Dimatteo, and C. Van Dyke Meperidine-induced delirium Am. J. Psychiatry 144 1987 1062 1065
13. P.A. Glare, T.D. Walsh, and C.E. Pippenger Normorphine, a neurotoxic metabolite? Lancet 335 1990 725 726
14. E. Bruera, and J. Pereira Acute neuropsychiatric findings in a patient receiving fentanyl for cancer pain Pain 69 1997 199 201
15. A. Vigano, D. Fan, and E. Bruera Individualized use of methadone and opioid rotation in the comprehensive management of cancer pain associated with poor prognostic indicators Pain 67 1996 115 119
16. D.M. Tomkins, and E.M. Sellers Addiction and the brain: the role of neurotransmitters in the cause and treatment of drug dependence CMAJ 164 2001 817 821
17. M.S. Cowen, and A.J. Lawrence The role of opioid-dopamine interactions in the induction and maintenance of ethanol consumption Prog. Neuropsychopharmacol. Biol. Psychiatry 23 1999 1171 1212
18. P.V. Piazza, and M. Le Moal Glucocorticoids as a biological substrate of reward: physiological and pathophysiological implications Brain Res. Brain Res. Rev. 25 1997 359 372
19. R.M. Allen, and S.J. Young Phencyclidine-induced psychosis Am. J. Psychiatry 135 1978 1081 1084
20. A. Alciati, B. Scaramelli, A. Fusi, E. Butteri, M.L. Cattaneo, and C. Mellado Three cases of delirium after "ecstasy" ingestion J. Psychoactive Drugs 31 1999 167 170
21. B.H. Westerink Can antipsychotic drugs be classified by their effects on a particular group of dopamine neurons in the brain? Eur. J. Pharmacol. 455 2002 1 18
22. R.A. Chambers, J.H. Krystal, and D.W. Self A neurobiological basis for substance abuse comorbidity in schizophrenia Biol. Psychiatry 50 2001 71 83
23. J.A. Lieberman, R.B. Mailman, and G. Duncan Serotonergic basis of antipsychotic drug effects in schizophrenia Biol. Psychiatry 44 1998 1099 1117
24. J.M. Davis Antipsychotic drugs H.I. Kaplan B.J. Sadock Comprehensive textbook of psychiatry 4th ed. 1985 Williams & Wilkins Baltimore (MD)
25. A.R. Feinstein Scientific standards in epidemiologic studies of the menace of daily life Science 242 1988 1257 1263
26. M. Egger, M. Schneider, and G. Davey Smith Spurious precision? Meta-analysis of observational studies BMJ 316 1998 140 144
27. A. Sawa, and S.H. Snyder Schizophrenia: diverse approaches to a complex disease Science 296 2002 692 695
28. K. Nakamura, M. Kurasawa, and Y. Tanaka Scopolamine model of delirium in rats and reversal of the performance impairment by aniracetam Drug Dev. Res. 43 1998 85 97
29. E. O'Hare, D.T. Weldon, K. Bettin, J. Cleary, and J.R. Mach Jr. Serum anticholinergic activity and behavior following atropine sulfate administration in the rat Pharmacol. Biochem. Behav. 56 1997 151 154